Key Takeaways
- Gradual recovery, still loss-making: Paste PVC volumes jumped 23% QoQ and CMCD stayed on track, but commodity-side losses from caustic soda and SPVC spreads kept the bottom line under pressure.
- Paste PVC got a regulatory tailwind: A court-ordered provisional assessment on EU and Japan imports tightened domestic supply from mid-September, supporting both volumes and pricing.
- CMCD is the value-creation bet: The pipeline is diversifying beyond agrochemicals into pharma and specialty materials, and management reiterated the ₹1,100 crores revenue target for FY28.
- SPVC spreads remain structurally fragile: Q2 spread was $199 per ton only because of a prior NRV provision reversal; the underlying spread was "very, very thin," and near-term volatility is expected to persist.
- What to watch next quarter: Whether paste PVC's regulatory support holds through the festive season, the pace of R32 customer qualifications, and any concrete update from the restructuring committee on separating specialty and commodity businesses.
Paste PVC: The Quarter's Bright Spot
- Demand surge: Domestic demand peaked in September, driven by automotive and footwear sectors, with buying activity healthy throughout the quarter and traction extending beyond the regular customer base.
- Supply-side support: Limited domestic material availability and constrained imports supported market prices; customers increased inventory purchases amid rising prices, translating into 23% sequential volume growth.
- Regulatory catalyst: The Madras High Court single bench directed provisional assessment of paste PVC imports from the EU and Japan, effective mid-September 2026; imports are now released only on furnishing PD bonds, and the government's appeal against the interim order was not entertained by the division bench.
- Product development underway: The company is working on new grades and adapting existing grades for special applications within standard end-uses like leather, upholstery and footwear, using only recipe and process changes on existing infrastructure with no additional capex.
- Near-term outlook: Domestic demand expected to remain healthy through the festive period; management remains confident about growth opportunities, supported by strong customer relationships and ongoing capacity enhancement initiatives.
Ganeshkumar: "We are working on a few streams on the paste PVC business, which is new grades development and also looking at our existing grades and improving, adapting them to some of the special applications. So, these are basically recipe and process changes which are done using the existing infrastructure."
CMCD: The Specialty Engine
- Strong quarter, strong visibility: The business continued to deliver a strong performance, supported by ramp-up of molecules commercialized over the past; healthy margins reflect the growing portfolio's strength, and a healthy order book provides good visibility for the rest of FY27.
- Pipeline diversification: Increasing opportunities beyond agrochemicals, with the pipeline expanding into pharmaceutical and other specialty chemical applications; dedicated business development teams in Europe and Japan are strengthening customer engagements and generating new product opportunities.
- Revenue trajectory: Revenue pace has increased; the company is "well on to achieve" the ₹1,000 crores revenue target by next year; this year will see "significant growth" over last year.
- Margin ambition: Management's stated intent is to reach a ±20% EBITDA level when the business scales up, with margins continuing to improve as revenue scales through operating leverage.
- Pre-commercial pipeline: Four pre-commercial products are in the pipeline, with some expected to be commercialized this financial year; Q4 is expected to be a strong quarter given typical dispatch weighting.
- Raw material management: Some products have raw material increases as a pass-through; on others, the company has had "good conversations" to share escalation while also improving efficiency to mitigate overall impact.
Rangachari: "The pipeline continues to be strong, and as we indicated in the last call, we have invested significant efforts in terms of business development, both in Europe as well as in Japan. The traction is both in AgChem, but significantly in non-AgChem. Some of it is in pharma and some of it is in other specialty materials."
SPVC & Commodity Headwinds
- SPVC pricing improved, but spreads tell the real story: Pricing improved sequentially due to rising crude oil and ethylene prices together with a sharp increase in ocean freight rates; the Minimum Import Price also helped stabilize prices to some extent. However, VCM prices are now catching up, pressuring spreads.
- Q2 spread was optically flattered: The reported Q2 spread was $199 per ton, but that included a reversal of a prior NRV provision; without that reversal, the underlying spread was "very, very thin."
- Structural oversupply persists: Near-term spreads are expected to remain volatile; structural oversupply continues to weigh on industry profitability. The aspirational spread goal is $200 per ton, which would take the company to a PBT-positive range.
- VCM price dynamics are cascading: VCM pricing is linked to caustic soda production; if caustic prices do not firm up, production goes down, chlorine prices go up, creating a cascading effect. VCM prices rose 12–14% in the last month.
- Caustic soda drag: Volumes were impacted by the Karaikal shutdown, which also constrained production at Mettur due to resulting chlorine disposal challenges; international prices continue to face pressure from excess Chinese supply and weak demand.
- Chloromethanes and hydrogen peroxide mixed: Chloromethanes volumes improved sequentially as production availability increased, but carbon tetrachloride faced subdued demand and pricing pressure amid inventory overhang and lower-priced Chinese imports. Hydrogen peroxide realizations improved sequentially, but production remained relatively lower due to limited hydrogen availability from lower caustic soda intake.
- High-cost inventory cleared: The high-cost VCM inventory that had impacted Q1 performance was largely consumed by August.
Ganeshkumar: "We have an established infrastructure, which is at a relatively lower capex. ... we may be price takers, but I think at the end of the day, in India, all of us are price takers. It works globally at a global parity price. There is an equilibrium that the market achieves."
Refrigerant Gases: Early-Stage Build
- R32 commercial production commenced: Commercial production of R32 from a swing plant began in May 2026; 2 kilo tons commissioned with a commissioning letter given to stock exchanges.
- Customer qualification in progress: Go-to-market initiatives have started; approximately 150 tons supplied in the market over the last four months with positive feedback on product specifications; global customers are reviewing specifications and sampling plans.
- Capacity expanded within existing capex: R32 capacity was increased from 14 kilo tons to 20 kilo tons through debottlenecking during the engineering phase, with the capex envelope unchanged; full 20 kilo tons capacity is expected to be operational by end of FY27 (Q4).
- Expansion timeline: New plants expected to commence commercial operations by end of FY27; the upcoming capacity expansion is expected to meaningfully enhance the ability to serve both domestic and export markets.
Restructuring & Trade Policy
- Restructuring committee update pending: Significant work has been done; the committee has looked at various options for specialty and commodity businesses with management input and engaged advisors; an update is expected "at the earliest."
- Anti-dumping duty lapsed: The SPVC anti-dumping duty application was allowed to lapse about 8–9 months back.
- Countervailing duty investigation underway: An anti-subsidy investigation against China is in progress; preliminary findings are in the public domain and will go through the government process before final findings and a Ministry of Finance decision.
- No major capex ahead: Beyond completion of the refrigerant gases project, only normal maintenance capex of approximately ₹60–70 crores is planned; the company is exploring different avenues for future growth but says it is "a bit early to comment" on what, size, or scale.
Profitability Path & Value Creation
- Profitability still weighed down: While EBITDA improved significantly during the quarter, profitability continues to be impacted by depreciation associated with recent capital investments, interest costs on existing borrowings, and losses in certain commodity businesses.
- No bottom-line guidance given: Management declined to give specific guidance on whether a positive bottom line can be expected in Q3 or Q4, citing dependence on VCM price evolution over the quarter; paste PVC has positive traction and CMCD is going as per plan, but the commodity side has challenges.
- Specialty seen as the value driver: Management acknowledged IPO investors' concerns explicitly, stating that specialty businesses will drive value creation in the coming years while noting that "commodity is commodity" and has been in a challenging situation for the past two to three years.
Muralidharan: "We do recognize that. ... We believe these businesses will add significant value to the company in the coming years. I think that is what will be the driving force for the valuation in the coming years. ... Commodity is commodity. We are seeing a challenging situation for the past two, three years. ... If you look at value creation, we believe the Specialty will drive the value creation for the company. We are sure, we are cognizant of the fact that people have come in at some price at the IPO, and we are cognizant that we should create value going forward."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| CMCD revenue target | Reach ₹1,100 crores revenue | Next year (FY27) |
| CMCD revenue milestone | Reach ₹1,000 crores revenue | FY27 |
| CMCD EBITDA margin | Achieve ±20% EBITDA level at scale | When scaled up (no date) |
| R32 capacity | Full 20 kilo tons operational | End of FY27 (Q4) |
| CMCD pre-commercial products | Some of 4 pre-commercial products commercialized | This financial year (FY27) |
| Capex | Only maintenance capex of ~₹60–70 crores beyond refrigerant gases project | Ongoing |
| Restructuring committee | Update on specialty/commodity separation options | "At the earliest" |
| SPVC aspirational spread | Achieve $200 per ton spread to reach PBT-positive range | Aspirational goal |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Consolidated revenue | ₹1,323 cr, +28% YoY |
| EBITDA | ₹111 cr, +158% YoY; ₹43 cr in Q2 FY26 and ₹115 cr in Q1 FY27 |
| EBITDA margin | 8%, vs 4% in Q2 FY26 |
| Net loss | ₹5 cr |
| Specialty chemicals revenue | ₹488 cr, +31% YoY and +14% QoQ |
| Value-added chemicals revenue | ₹120 cr, vs ₹138 cr in Q2 FY26 |
| Suspension PVC revenue | ₹715 cr, +37% YoY and +26% QoQ |
| H1 FY27 consolidated revenue | ₹2,448 cr, +15% vs ₹2,133 cr in H1 FY26 |
| H1 FY27 net loss | ₹181 cr |
| Consolidated gross debt | ₹1,748 cr as of Sep 30, 2026 |
| Paste PVC sales volume growth | +23% QoQ |
| CMCD pipeline | ~50 molecules, with 14 commercial, ~4 pre-commercial, and 35–40 in development or RFQ stage |
| R32 capacity commissioned | 2 kt of 20 kt total; full capacity expected by end of FY27 |
| R32 sales to date | ~150 tons supplied over the last four months |
| SPVC spread in Q2 | $199 per ton, including reversal of prior NRV provision; spread was very thin without it |